Literature DB >> 21054173

Antiestrogens and their therapeutic applications in breast cancer and other diseases.

Simak Ali1, Laki Buluwela, R Charles Coombes.   

Abstract

The identification of the link between breast cancer and estrogens has led to the development of antiestrogens, in particular tamoxifen, to inhibit the activities of estrogen receptors (ERs) in breast cancer cells. The clinical use of tamoxifen has played a major part in decreasing breast cancer mortality over the past 30 years. Though antiestrogenic in the breast, some antiestrogens have estrogen-like actions in other tissues, acting to promote bone density and protect against cardiovascular disease, thus raising the possibility of their use in counteracting the effects of estrogen loss following menopause. Moreover, antiestrogens show efficacy as chemopreventive agents in women at high risk of developing breast cancer. Thus, antiestrogens define an important and well-understood class of cancer drug, which continue to be a mainstay in breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21054173     DOI: 10.1146/annurev-med-052209-100305

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  31 in total

1.  Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.

Authors:  F Cerrato; M E Fernández-Suárez; R Alonso; M Alonso; C Vázquez; O Pastor; P Mata; M A Lasunción; D Gómez-Coronado
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

2.  PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.

Authors:  Doudou Huang; Lin Tang; Fang Yang; Juan Jin; Xiaoxiang Guan
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 3.  Optimizing mouse models for precision cancer prevention.

Authors:  Clémentine Le Magnen; Aditya Dutta; Cory Abate-Shen
Journal:  Nat Rev Cancer       Date:  2016-02-19       Impact factor: 60.716

4.  Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy.

Authors:  Walckiria G Romero; Fabrício B Da Silva; Mariana V Borgo; Nazaré S Bissoli; Sonia A Gouvêa; Gláucia R Abreu
Journal:  Oncologist       Date:  2012-04-04

5.  Voltage-dependent open-channel block of G protein-gated inward-rectifying K(+) (GIRK) current in rat atrial myocytes by tamoxifen.

Authors:  Svenja Vanheiden; Lutz Pott; Marie-Cécile Kienitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-25       Impact factor: 3.000

6.  Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell lines.

Authors:  Lois A Annab; Carl D Bortner; Marie I Sifre; Jennifer M Collins; Ruchir R Shah; Darlene Dixon; H Karimi Kinyamu; Trevor K Archer
Journal:  Differentiation       Date:  2012-08-18       Impact factor: 3.880

7.  Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.

Authors:  Xihong Zhang; Michael R Diaz; Douglas Yee
Journal:  Breast Cancer Res Treat       Date:  2013-05-18       Impact factor: 4.872

8.  Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.

Authors:  Luca Magnani; Alexander Stoeck; Xiaoyang Zhang; András Lánczky; Anne C Mirabella; Tian-Li Wang; Balázs Gyorffy; Mathieu Lupien
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

9.  Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.

Authors:  Carl Blomqvist; Diana Eccles; Heli Nevanlinna; Sofia Khan; Rainer Fagerholm; Sajjad Rafiq; William Tapper; Kristiina Aittomäki; Jianjun Liu
Journal:  Clin Cancer Res       Date:  2015-05-11       Impact factor: 12.531

10.  Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.

Authors:  Georgios Nteliopoulos; Karen Page; Allison Hills; Karen Howarth; Warren Emmett; Emma Green; Luke J Martinson; Daniel Fernadez-Garcia; Robert Hastings; David S Guttery; Laura Kenny; Justin Stebbing; Susan Cleator; Farah Rehman; Kelly L T Gleason; Andrijac Sanela; Charlotte Ion; Amelia J Rushton; Nitzan Rosenfeld; R Charles Coombes; Jacqueline A Shaw
Journal:  Breast Cancer Res Treat       Date:  2021-06-07       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.